Readily Diagnostics
PrivateLast Round
VC Round
Oct 30, 2024
Total Funding Raised
$930,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Readily Diagnostics operates in Healthcare & Life Sciences and is based in Uppsala. Its latest recorded funding round was a VC Round in October 2024.
Readily Diagnostics is a medical technology company that develops rapid, instrument-free molecular diagnostic tests for infectious diseases using padlock probe technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Readily Diagnostics Comparables
Compare Readily Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GRIP Molecular Technologies | 74% | |
| OraSure Technologies Inc | 71% | |
| Fuse Diagnostics | 71% |
For institutional investors. Book with your work email.
Readily Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 30, 2024 | ||||
| Grant | Sep 4, 2024 | ||||
| Seed | Aug 2, 2023 |
For institutional investors. Book with your work email.
Readily Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Uppsala Innovation Centre | Seed |
| European Regional Development Fund | Grant |
| Almi Invest AB | Seed, VC Round |
| Länsförsäkringar Uppsala | VC Round |
| Bio-X Accelerate Program | Grant |
| Uppsala University Invest | Seed, VC Round |
| Kjell och Märta Beijers Stiftelse | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 66% MoM, reaching 2.3K.
- Jan 13, 2025
Grew 67% QoQ from 6 to 10 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 2, 2026
In Sweden, Readily Diagnostics AB plans to use a $970,000 grant to develop an affordable point-of-care test for chlamydia, gonorrhea and trichomoniasis that potentially flags drug-resistant gonorrhea, with testing designed for primary care, family planning and HIV-prevention settings, in Sep '26.
- receives_financingAug 27, 2026
On Aug 27th '26, Readily Diagnostics AB receives a $970K grant from the Gates Foundation to support early concept and feasibility work on an affordable point-of-care test for chlamydia, gonorrhea and trichomoniasis in Sweden.
- is_developingAug 27, 2026
Readily Diagnostics AB is developing a point-of-care platform that delivers molecular diagnostic results near patients without central laboratories, targets chlamydia, gonorrhea, and trichomoniasis, and is designed to detect antibiotic-resistance markers in gonorrhea.
- is_developingAug 27, 2026
Readily Diagnostics AB receives an approximately €811k grant from the Gates Foundation on Aug 27th '26 in Sweden to support early concept and feasibility work on an affordable point-of-care test for chlamydia, gonorrhea and trichomoniasis, including sample preparation, antimicrobial resistance detection and a product-development roadmap.
For institutional investors. Book with your work email.
Readily Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Readily Diagnostics's valuation, stock price, and market status.
Is Readily Diagnostics a public or private company?
Readily Diagnostics is a private company.
What is the current stock price of Readily Diagnostics?
Readily Diagnostics is a private company, so its shares have no public market price. Caplight tracks Readily Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Readily Diagnostics worth (valuation)?
Valuation information for Readily Diagnostics is not publicly available.
Can I buy Readily Diagnostics stock?
Readily Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Readily Diagnostics's last funding round?
Readily Diagnostics's most recent funding round was VC Round on October 30, 2024.
Who are the main investors in Readily Diagnostics?
Key investors in Readily Diagnostics include Uppsala Innovation Centre, European Regional Development Fund, Almi Invest AB, Länsförsäkringar Uppsala, Bio-X Accelerate Program.
Will Readily Diagnostics IPO soon?
No public IPO plans have been announced for Readily Diagnostics.
How can I track Readily Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in Readily Diagnostics's shares on secondary markets.